CDTX - シダラ・セラピュ―ティクス （Cidara Therapeutics Inc.） シダラ・セラピュ―ティクスCDTXのチャート
CDTXの企業情報
| symbol | CDTx |
|---|---|
| 会社名 | Cidara Therapeutics Inc （シダラ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 シダラ・セラピューティクス（Cidara Therapeutics Inc.）（旧名：K2 Therapeutics Inc.）は抗感染製品の発見・開発・商品化に従事するバイオ企業である。同社はエキノカンジンである化合物製剤CD101を提供する。その製品はCD101静脈注射（biofungin）及びCD101トピカル（topifungin）を含む。また、免疫療法技術プラットフォーム「Cloudbreak」を所有する。同社はまた、細菌及びウイルス感染の治療用その他候補薬剤の開発を行う。CD101 IV及びCD101 topicalは前臨床開発の初期段階にある。同社の「Cloudbreak」開発候補薬剤はC001及びC016を含む。また、マウス及びモルモットにおけるC001の許容性、毒性及び薬物動態プロファイルを評価するための前臨床研究を行った。「Cloudbreak」開発候補薬剤は前臨床研究の前臨床原理証明（POP）有効性・安全性を実証した。 シダラ・セラピュ―ティクスは米国のバイオ企業。不十分な治療法による疾患のための新抗感染薬の発見、開発、実用化に焦点を当て事業を展開。CD101は抗真菌薬として実績のあるエキノカンジンであり、全身性真菌感染症の治療・予防にCD101 IV、外陰膣カンジダ症治療薬CD101 topical、流行粘膜感染症治療にCD101 VVCを開発する。 Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. |
| 本社所在地 | 6310 Nancy Ridge Drive Suite 101 San Diego CA 92121 USA |
| 代表者氏名 | Scott M. Rocklage Scott M. Rocklage |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-752-6170 |
| 設立年月日 | 41244 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 61人 |
| url | www.cidara.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cdtx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -57.11200 |
| 終値（lastsale） | 4.315 |
| 時価総額（marketcap） | 119437003.665 |
| 時価総額 | 時価総額（百万ドル） 108.36520 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 15.07520 |
| 当期純利益 | 当期純利益（百万ドル） -69.06900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cidara Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 44% to $43.4M. Higher net loss reflects Research and development - increase of 8% to $24.1M (expense) General and administrative - increase of 8% to $5.5M (expense) Stock-based Compensation in SGA increase of 12% to $1.7M (expense). |
CDTXのテクニカル分析
CDTXのニュース
Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference 2021/06/14 12:00:00 Intrado Digital Media
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference, being held virtually June 21-23, 2021.
Cidara to Present at Mycology 2021 Conference 2021/06/02 00:00:00 BioSpace
Cidara Therapeutics, Inc. announced that it will virtually present highlights from pre-clinical through Phase 2 clinical trial data evaluating rezafungin, Cidaras novel, once-weekly echinocandin, for the treatment and prevention of invasive fungal disease at the Mycology 2021 Conference, which takes place online from June 11-12, 2021.
Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP) and Cidara Therapeutics (CDTX) 2021/05/14 11:05:25 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Armata Pharmaceuticals (ARMP) and Cidara The post Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP) and Cidara Therapeutics (CDTX) appeared first on Smarter Analyst .
Cidara Therapeutics: Q1 Earnings Snapshot 2021/05/13 22:33:39 CityNews Toronto
SAN DIEGO (AP) _ Cidara Therapeutics Inc. (CDTX) on Thursday reported a loss of $18.3 million in its first quarter. The San Diego-based company said it had a loss of 39 cents per share. The biopharmaceutical company posted revenue of $2.4 million in the period. In the final minutes of trading on Thursday, the companys []
65 Biggest Movers From Yesterday 2020/11/13 10:02:08 Benzinga
Gainers IMAC Holdings, Inc. (NASDAQ: IMAC ) shares climbed 83.3% to close at $1.52 on Thursday after the company reported the purchase of Lockwood Chiropractic in Webster Groves, Missouri and announced Q3 results. Allied Healthcare Products, Inc. (NASDAQ: AHPI ) jumped 67.2% to close at $7.86. EuroDry Ltd. (NASDAQ: EDRY ) shares gained 58.1% to close at $7.10 after the company swung to a profit in the third quarter. Pyxis Tankers Inc. (NASDAQ: PXS ) gained 40.6% to close at $1.18. Pyxis Tankers is scheduled to release Q3 results on November 13. XPeng Inc. (NYSE: XPEV ) gained 33.4% to close at $44.73 after the company reported Q3 results. Celsius Holdings, Inc. (NASDAQ: CELH ) surged 29% to close at $31.96 after the company reported better-than-expected Q3 results. Electrameccanica Vehicles Corp. (NASDAQ: SOLO ) rose 28.1% to close at $4.83. Li Auto Inc. (NASDAQ: LI ) shares gained 27.3% to close at $31.78. Li Auto reported last week it is recalling some of its Li ONE vehicle models, and the Chinese electric vehicle manufacturer's stock was retreating in reaction.
Insider Buys Cidara Therapeutics Stock 2020/11/12 11:58:00 Benzinga
Shares of Cidara Therapeutics Inc (NASDAQ:CDTX) rose 25% from the previous closing price. A Form 4 filing filed with the SEC on Tuesday, …
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results 2020/11/05 21:24:00 GlobeNewswire
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics…
Cidara Therapeutics : Corporate Presentation - August 2020 | MarketScreener 2020/08/13 20:23:03 MarketScreener
New Hope for Serious Infections Corporate Presentation August 2020 ©… | August 13, 2020
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference 2020/06/11 12:00:00 GlobeNewswire
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to…
Cidara Therapeutics : Corporate Presentation - August 2020 | MarketScreener 2020/08/13 20:23:03 MarketScreener
New Hope for Serious Infections Corporate Presentation August 2020 ©… | August 13, 2020
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference 2020/06/11 12:00:00 GlobeNewswire
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to…
What Makes Cidara Therapeutics (CDTX) a New Strong Buy Stock 2020/05/05 16:00:07 Zacks Investment Research
Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics 2020/01/28 12:12:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN )) Cidara Therapeutics Inc (NASDAQ: CDTX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )(saw a coronavirus-induced rally ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(reacted to its Q3 results) Inovio Pharmaceuticals Inc (NASDAQ: INO )(announced Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) SI-Bone Inc (NASDAQ: SIBN ) Vaccinex Inc (NASDAQ: VCNX ) Vir Biotechnology Inc (NASDAQ: VIR ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 27) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Correvio Pharma Corp (NASDAQ: CORV ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Heat Biologics Inc (NASDAQ: HTBX ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) MediciNova, Inc.
Cidara Rallies On Development Deal For Lead Antifungal Medication 2019/09/03 19:22:12 Benzinga
Cidara Therapeutics Inc (NASDAQ: CDTX ) shares were advancing by more than 50% Tuesday after the thinly traded, micro-cap biotech announced a development and commercialization deal for its lead medication rezafungin. The Deal Cidara said it has entered into a strategic partnership with U.K.-based, privately held Mundipharma, under which it will grant Mundipharma exclusive commercialization rights to rezafungin outside the U.S. and Japan. In exchange, Cidara stands to receive a $30-million upfront payment and an additional $42 million in near-term funding to finance the global Phase 3 ReSTORE and ReSPECT trials … Full story available on Benzinga.com